Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).

Ramil, G, Pratcorona, M, Nomdedéu, JF. Be aware of the X: BCOR mutations in myeloid neoplasms. HAEMATOLOGICA. 2024; 109(6)DOI:10.3324/haematol.2023.284748. PMID:38328862. IF:10.100(Q1/2D).

Virgili, AC, Salazar, J, Gallardo, A, López-Pousa, A, Terés, R, Bagué, S, Orellana, R, Fumagalli, C, Mangues, R, Alba-Castellón, L, Unzueta, U, Casanova, I, Sebio, A. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas. Diagnostics. 2024; 14(11)DOI:10.3390/diagnostics14111195. PMID:38893721. IF:3.300(Q1/2D).